NEW YORK, June 3, 2026, 05:05 (EDT)
- Acadia Healthcare (ACHC) finished Tuesday higher, settling at $24.42, a gain of 4.76%. About 2.3 million shares changed hands.
- Wall Street looked set for a wary start Wednesday, while U.S. futures stalled around all-time highs.
- Acadia turned in a higher first-quarter operating profit, but investors are looking at legal costs, payer denials, and a fresh jury award against a subsidiary.
Acadia Healthcare Company shares climbed Tuesday, beating gains in the major U.S. indexes, as buyers stuck with the behavioral-health hospital operator’s shaky turnaround story.
The stock ended Nasdaq trading at $24.42, gaining $1.11, or 4.76%. About 2.32 million shares changed hands, roughly matching recent volume. Shares are still below the 52-week high of $30.20.
Wall Street’s record run gives Acadia firmer ground, but risks remain
U.S. index futures traded flat to down early Wednesday after all three major Wall Street indexes set new records on Tuesday, with the S&P 500 closing above 7,600 for the first time, Reuters said. That helps Acadia, but it doesn’t clear the way completely.
Acadia is still focused on fixing its business. The company, based in Franklin, Tennessee, operates acute inpatient psychiatric hospitals, specialty treatment centers, comprehensive treatment centers, and residential facilities in the U.S. and Puerto Rico, a filing shows.
Acadia’s latest earnings report had some positives for bulls. The company posted a 7.6% jump in first-quarter revenue to $828.8 million. Same-facility revenue was up 7.3%. Adjusted EBITDA, which excludes some items, came in at $144.2 million, up from $134.2 million the year before.
Acadia Healthcare CEO Debbie Osteen said in the April results release that “the good start to the year reflects disciplined execution throughout Acadia,” citing strong patient volumes in acute and residential treatment. That helped the company beat its adjusted EBITDA guidance. Acadia Healthcare Company, Inc.
Analyst calls are mixed. StockAnalysis data puts the average view at “Buy” from 14 analysts, with a 12-month price target of $28.46. But the spread is wide: Mizuho is at Hold and a $27 target, while Raymond James kept Buy and sees $39. Bank of America Securities kept its Sell call and a $13 target after the April earnings. StockAnalysis
That’s the story. Acadia beat forecasts on revenue, adjusted EPS and adjusted EBITDA in the first quarter, according to StockStory, but warned of ongoing pressure at some specialty sites in Pennsylvania, weather hits in its comprehensive treatment centers, and more payer denials.
Peer action didn’t provide much lift for the group early Wednesday. Universal Health Services fell about 1.5% in early trading; HCA Healthcare, a bigger hospital operator, slipped around 1.0%. That left Acadia’s jump on Tuesday standing out as more of a single-stock move, not a wider hospital trade.
But the downside risk is material. Acadia disclosed in a May 18 filing that a California jury hit its Fashion Valley CTC unit with $35 million in compensatory damages and $70 million in punitive damages over an employment suit. The company said the subsidiary denied the claims, would fight the verdict, and couldn’t guarantee the damages would be lowered.
Legal and regulatory costs are still a factor. Acadia said first-quarter transaction, legal and related costs totaled $12.4 million due to government investigations. That’s lower than $31.0 million last year. Further claims, payer denials, or adverse rulings could pressure margins and complicate the earnings recovery.
Investors are weighing the stock on whether Osteen’s operating changes last more than a single quarter. The big focus now is on second-quarter guidance. Acadia said it expects revenue of $835 million to $850 million, and adjusted EBITDA between $142 million and $152 million. The company did not factor in any new supplemental payments.
